VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease

Summary

This is a multicenter, randomized, double-blind placebo-controlled, parallel group study to evaluate the efficacy and safety of VTX958 in participants with moderately to severely active Crohn's Disease.

Timeline

Start

2023-01-25

Primary completion

2024-06-27

Completion

2024-12-20

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision”

Drugs

Indications